LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Начало・Списък с акции・ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

22.27 26.61

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

17.49

Максимум

25.11

Ключови измерители
By Trading Economics
Приходи	-125M 19M
Продажби	-15M 244M
P/E Средно за сектора	12.882 56.602
EPS	0.11
Марж на печалбата	7.771
Служители	653
EBITDA	7.1M 19M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+48.25% upside

Дивиденти
By Dow Jones
Следващи печалби	5.08.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-367M 2.9B
Предишно отваряне	-4.34
Предишно затваряне	22.27

Настроения в новините

By Acuity

31%

69%

88 / 382 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

14.845 / N/A Подкрепа & съпротива

ACADIA Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

15.05.2025 г., 22:52 ч. UTC

Печалби

Значими двигатели на пазара

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

15.05.2025 г., 20:37 ч. UTC

Топ новини

Печалби

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

16.05.2025 г., 00:00 ч. UTC

Пазарно говорене

Xero Bull Stays Positive on Cost Outlook -- Market Talk

15.05.2025 г., 23:47 ч. UTC

Пазарно говорене

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

15.05.2025 г., 23:38 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

15.05.2025 г., 23:38 ч. UTC

Пазарно говорене

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15.05.2025 г., 23:14 ч. UTC

Топ новини

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

15.05.2025 г., 22:46 ч. UTC

Топ новини

Придобивния, сливания и поглъщания

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15.05.2025 г., 22:46 ч. UTC

Придобивния, сливания и поглъщания

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15.05.2025 г., 22:46 ч. UTC

Придобивния, сливания и поглъщания

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15.05.2025 г., 22:46 ч. UTC

Придобивния, сливания и поглъщания

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15.05.2025 г., 21:58 ч. UTC

Печалби

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

15.05.2025 г., 21:24 ч. UTC

Печалби

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

15.05.2025 г., 20:56 ч. UTC

Пазарно говорене

U.S. Spending Downturn Could Lie Ahead -- Market Talk

15.05.2025 г., 20:54 ч. UTC

Пазарно говорене

Печалби

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

15.05.2025 г., 20:54 ч. UTC

Печалби

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

15.05.2025 г., 20:51 ч. UTC

Печалби

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

15.05.2025 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

15.05.2025 г., 20:50 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

15.05.2025 г., 20:50 ч. UTC

Печалби

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

15.05.2025 г., 20:47 ч. UTC

Печалби

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

15.05.2025 г., 20:47 ч. UTC

Печалби

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

15.05.2025 г., 20:47 ч. UTC

Печалби

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

15.05.2025 г., 20:47 ч. UTC

Печалби

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

15.05.2025 г., 20:37 ч. UTC

Печалби

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

15.05.2025 г., 20:37 ч. UTC

Печалби

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

15.05.2025 г., 20:37 ч. UTC

Печалби

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

15.05.2025 г., 20:37 ч. UTC

Печалби

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

15.05.2025 г., 20:26 ч. UTC

Топ новини

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

15.05.2025 г., 20:25 ч. UTC

Печалби

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

ACADIA Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

48.25% нагоре

12-месечна прогноза

Среден 25.44 USD 48.25%

Висок 37 USD

Нисък 18 USD

Според 16 анализатори от Wall Street, предложили 12-месечна ценова цел за ACADIA Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

16 ratings

Купи

Задържане

Продай

Според 16 анализатори, дали борсови рейтинги на ACADIA Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

14.845 / N/AПодкрепа & съпротива

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

88 / 382 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.